Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) is a biopharmaceutical company that focuses on the development and marketing of treatment products in the areas of respiratory disease, allergy, oncology and immunology. The company’s current pharmaceutical products include the Epinephrine Injection PFS syringe for treating anaphylaxis, APC-1000 and APC-5000 for treating asthma and chronic obstructive pulmonary disease, APC-2000 for treating bronchospasms, and APC-3000, an HFA nasal steroid product for treating allergic rhinitis. Adamis’ vaccine and cancer drug products include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for treating prostate cancer. For more information, visit the company’s website at www.adamispharmaceuticals.com